Trial Profile
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Ispinesib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 05 Dec 2006 Status change
- 19 Aug 2005 New trial record.